Outcomes following bioprosthetic valve replacement in prior non‐cardiac transplant recipients. Issue 11 (13th October 2019)

• Record Type: Journal Article
• Authors: Bozso, Sabin J.; Kang, Jimmy J. H.; Al‐Adra, David; Hong, Yongzhe; Moon, Michael C.; Freed, Darren H.; Nagendran, Jayan; Nagendran, Jeevan
• Is Part Of: Clinical transplantation. Volume 33:Issue 11(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-10-13
• Subjects: transplantation -- xenograft valve replacement; Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ctr.13720
• Languages: English
• ISSNs: 0902-0063

Abstract

Abstract: Background: We report on overall survival and valve‐related outcomes after bioprosthetic valve replacement in prior transplant recipients. Methods: From January 2004 to December 2018, 20 consecutive patients (mean age 65.7‐years, 90% male) with prior non‐cardiac transplantation underwent bioprosthetic aortic (n = 18) or combined aortic and mitral (n = 2) valve replacement. Patients consisted of kidney (n = 14), lung (n = 2), liver (n = 3), and bone‐marrow (n = 2) transplants with the most common indication for valve replacement being calcific degeneration (n = 12). Outcomes were measured over a 12‐year span, with a median follow‐up duration of 3.9 years. Results: Overall survival at 30 days was 100% and at median follow‐up was 60%. Acute kidney injury occurred in 50% (n = 10) with temporary dialysis required in 5% (n = 1) and 15% (n = 3) suffered respiratory failure. No patients experienced major bleeding, heart failure, or sternal wound infection. No patients required redo valve replacement during the study period. Conclusions: Our results provide contemporary data demonstrating that patients with prior transplant can undergo bioprosthetic valve replacement with acceptable inhospital mortality rates and long‐term survival, with a low rate of major morbidity. Furthermore, bioprosthetic valve replacement is a viable option in this group of patients with no redo valve replacement and acceptable long‐term hemodynamic valvular function.